Related Experiment Video
Updated: Jun 5, 2026
05:31
Disruption of the Mouse Blood-Brain Barrier by Small Extracellular Vesicles from Hypoxic Human Placentas
Published on: January 26, 2024
PP13 as a marker of pre-eclampsia: A two platform comparison study
N J Cowans1, A Stamatopoulou, A Khalil
1Prenatal Research Unit, Clinical Biochemistry Department, King George Hospital, Goodmayes IG3 8YB, UK.
Placenta
|January 25, 2011
Summary
This study compared two methods for measuring placental protein 13 (PP13) to assess its role in predicting pre-eclampsia (PE). PP13 levels were lower in pre-eclampsia cases, with differences observed between the two assay platforms.
Area of Science:
- Reproductive biology
- Biochemistry
- Clinical diagnostics
Background:
- Pre-eclampsia (PE) is a significant complication of pregnancy.
- Early detection of PE is crucial for maternal and fetal well-being.
- Placental protein 13 (PP13) is a potential biomarker for pregnancy complications.
Purpose of the Study:
- To evaluate placental protein 13 (PP13) as a predictive marker for pre-eclampsia (PE).
- To compare the performance of two different immunoassay platforms (DTL ELISA and AutoDELFIA®) for PP13 measurement.
Main Methods:
- A case-control study analyzed first-trimester serum samples.
- Samples were from 195 normal pregnancies and 37 pregnancies with PE.
- PP13 levels were measured using a manual DTL ELISA and the AutoDELFIA® platform.
Main Results:
- PP13 levels increased with gestational age in both control and PE groups.
- Significantly decreased PP13 levels were observed in women with PE.
- The DTL ELISA showed a more pronounced reduction in PP13 levels in PE cases compared to AutoDELFIA®.
Conclusions:
- PP13 shows potential as a biomarker for pre-eclampsia.
- Further research is required to compare the reproducibility, robustness, and clinical utility of the DTL ELISA and AutoDELFIA® PP13 assays for PE prediction.
